Gene · 50484
RRM2B: ribonucleotide reductase regulatory TP53 inducible subunit M2B
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. RRM2B: ribonucleotide reductase regulatory TP53 inducible subunit M2B. Genes, record 50484. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/50484
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q7LG56 | Ribonucleoside-diphosphate reductase subunit M2 B | 351 | 3 | Ensembl, GeneID, HGNC |
Source UniProt
Patents24
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 61939 | Q7LG56 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 1359 | Q7LG56 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 986 | Q7LG56 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 3786 | Q7LG56 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 3786 | Q7LG56 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 986 | Q7LG56 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 1359 | Q7LG56 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 73874 | Q7LG56 | Espacenet |
| US 11400116 B2 | 2022-08-02 | 4116 | Q7LG56 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 176845 | Q7LG56 | Espacenet |
1 to 10 of 24
See all 24 patentsDrugs10
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| CLOFARABINE | CHEMBL1750 | Ribonucleoside-diphosphate reductase RR1 inhibitor | INHIBITOR | ChEMBL |
| FLUDARABINE PHOSPHATE | CHEMBL1096882 | Ribonucleoside-diphosphate reductase RR1 inhibitor | INHIBITOR | ChEMBL |
| GALLIUM NITRATE | CHEMBL1200983 | Ribonucleoside-diphosphate reductase RR1 inhibitor | INHIBITOR | ChEMBL |
| GEMCITABINE | CHEMBL888 | Ribonucleoside-diphosphate reductase RR1 inhibitor | INHIBITOR | ChEMBL |
| GEMCITABINE HYDROCHLORIDE | CHEMBL1637 | Ribonucleoside-diphosphate reductase RR1 inhibitor | INHIBITOR | ChEMBL |
| HYDROXYUREA | CHEMBL467 | Ribonucleoside-diphosphate reductase RR1 inhibitor | INHIBITOR | ChEMBL |
| MOTEXAFIN GADOLINIUM | CHEMBL3544910 | Ribonucleoside-diphosphate reductase RR1 inhibitor | INHIBITOR | ChEMBL |
| TEZACITABINE | CHEMBL3989496 | Ribonucleoside-diphosphate reductase RR1 inhibitor | INHIBITOR | ChEMBL |
| TEZACITABINE ANHYDROUS | CHEMBL2105467 | Ribonucleoside-diphosphate reductase RR1 inhibitor | INHIBITOR | ChEMBL |
| TRIAPINE | CHEMBL231616 | Ribonucleotide reductase inhibitor | INHIBITOR | ChEMBL |
Trials3,175
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07604766 | GEMCITABINE | PHASE3 | ClinicalTrials.gov | |
| NCT07603557 | FLUDARABINE PHOSPHATE | PHASE2 | ClinicalTrials.gov | |
| NCT07602140 | GEMCITABINE | PHASE2 | ClinicalTrials.gov | |
| NCT07598318 | GEMCITABINE | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07579195 | GEMCITABINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07575191 | GEMCITABINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07570849 | GEMCITABINE | PHASE2 | ClinicalTrials.gov | |
| NCT07570823 | GEMCITABINE | PHASE3 | ClinicalTrials.gov | |
| NCT07570017 | GEMCITABINE | PHASE1 | ClinicalTrials.gov | |
| NCT07569679 | GEMCITABINE | PHASE2 | ClinicalTrials.gov |
1 to 10 of 3,175
See all 3,175 trialsNIH grants905
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | RRM2B papers | Newest fiscal year |
|---|---|---|---|
| P30CA043703 | Case Comprehensive Cancer Center Support Grant | 10 | 2025 |
| P30CA033572 | Cancer Center Support Grant | 8 | 2025 |
| ZIAES065078 | Molecular Characterization Of The Mitochondrial Dna Polymerase | 8 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 7 | 2025 |
| P30CA016056 | Roswell Park Cancer Center Support Grant | 6 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 5 | 2025 |
| ZIAES065080 | Human Mitochondrial Dna Polymerase With Anti-hiv Nucleotides | 5 | 2025 |
| P30CA010815 | Consolidated Basic Cancer Research Program | 4 | 2025 |
| R01NS049206 | Huntington's Disease Repeat Instability and Pathogenesis | 4 | 2025 |
| T32CA009171 | Training Program in Basic Cancer Research | 4 | 2025 |
1 to 10 of 905Source NIH's project files
See all 905 nih grantsPapers1,270
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Mechanisms of Hydroxyurea-Mediated DNA Damage Potentiation in Fanconi Anemia Cells. | Int J Mol Sci | 2026 | 42589438 | PubTator, text mining | PubMed |
| RRM2B is associated with low-level viremia during entecavir therapy in pediatric chronic hepatitis B and promotes profibrotic signaling in vitro. | Virol J | 2026 | 42436559 | PubTator, text mining | PubMed |
| Harmane induces apoptosis through RRM2B and suppresses colorectal cancer progression. | mSystems | 2026 | 42262096 | PubTator, text mining | PubMed |
| Multi-omics integration provides biological insight and prioritizes potential drug targets in multiple sclerosis progression. | J Neuroinflammation | 2026 | 42231304 | PubTator, text mining | PubMed |
| Microcavitary Alginate Hydrogel Reverses Chondrocyte Dedifferentiation via Temporal Modulation of the p53 Pathway. | Ann Biomed Eng | 2026 | 42098489 | PubTator, text mining | PubMed |
| Roles of RRM2 and RRM2B in pyrimidine stress responses and differentiation of acute myeloid leukemia cells. | Cell Death Discov | 2026 | 42031709 | PubTator, text mining | PubMed |
| Adaptive Regulation of dNTP Homeostasis Confers Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma. | Cancer Res | 2026 | 41941751 | PubTator, text mining | PubMed |
| Huntingtin (HTT) interactome in regulation of DNA repair/remodeling and RNA processing pathways. | Life Sci Alliance | 2026 | 41850723 | PubTator, text mining | PubMed |
| A Novel Truncating Pathogenic Variant in RRM2B in a Kurdish Family With Autosomal-Dominant Chronic Progressive External Ophthalmoplegia Plus (PEOA5). | J Clin Neuromuscul Dis | 2026 | 41766080 | PubTator, text mining | PubMed |
| Effect of a standardized meal on inflammatory biomarkers. | Scand J Clin Lab Invest | 2026 | 41689559 | PubTator, text mining | PubMed |
1 to 10 of 1,270
See all 1,270 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/50484
GET https://conductscience.org/api/genes/v1/50484/patents?page=2